Sinclair Pharma (“Sinclair”, http://www.sinclair.com) a global aesthetics company headquartered in London and wholly owned subsidiary of Huadong Medicine Company Limited announces that it has signed an exclusive product license and worldwide distribution agreement for Preime DermaFacial from EMA Aesthetics Limited for all territories outside of the UK and Germany.
LONDON , May 12, 2022 /PRNewswire-PRWeb/ –Sinclair Pharma (“Sinclair”, http://www.sinclair.com) a global aesthetics company headquartered in London and wholly owned subsidiary of Huadong Medicine Company Limited announces that it has signed an exclusive product license and worldwide distribution agreement for Preime DermaFacial from EMA Aesthetics Limited for all territories outside of the UK and Germany.
Launched in March 2022 at the World Congress of Anti-Aging Medicine in Monaco, the PrÃ©ime DermaFacial therapy offers five powerful technologies and is designed to enable the curation of personalized treatments. The technology was designed with skin care practitioners in mind and focuses on efficacy, unlimited treatment combinations and ease of use. The PrÃ©ime DermaFacial platform can be the main skin care platform for clinics, aesthetic centers and medspas.
The PrÃ©ime DermaFacial is a smart device, powered by IoT (Internet of Things) technology, designed to ensure consistent results and customer satisfaction. Designed and manufactured in Europethe PrÃ©ime DermaFacial associated with PrÃ©ime consumables is the new world reference in terms of skin care.
Miguel Pardos, CEO of the Sinclair EBD Division, said: âWe are very pleased to partner with EMA for the global commercialization of PrÃ©ime DermaFacial. We see PrÃ©ime DermaFacial as a game-changer in the aesthetic market. Their flexibility to respond to high-demand treatments along with the combination of technologies makes PrÃ©ime DermaFacial a must-have for any aesthetic practice. Sinclair’s EBD expertise, scale, direct presence in key markets and our extensive distribution channels will accelerate the market penetration and growth of PrÃ©ime DermaFacial globally.
The founder and CEO of EMA Aesthetics, Malcolm Wall Morriscommented, âSince its inception, EMA’s primary goal has been to focus on creating products designed to deliver excellent patient outcomes and an enhanced user experience for clinics and therapists. Since the unveiling of the DermaFacial Preime at the World Congress of Aesthetics and Anti-Aging Medicine in Monaco in March 2022, the EMA received unprecedented feedback regarding the system’s design, combined technologies, processing options and IoT capabilities. We are delighted to partner with Sinclair who, through its EDB subsidiary, Cocoon, is uniquely positioned to accelerate the global commercialization of the world’s most advanced aesthetic facial device. Â»
About Huadong Medicine Co., Ltd.
HMC (SZ.000963), listed in 1999, is one of the leading manufacturers and distributors of pharmaceutical and medical products in Chinawhere it has more than 12,000 employees and has generated approximately $5.1 billion of turnover for the financial year ended December 31, 2021. Over the past five years, HMC has established a leading detailing business in China, offering a variety of fillers. HMC is a subsidiary of China Grand Enterprise Inc. (CGE), an investment group headquartered in beijing. CGE has four business segments: Pharmaceuticals and Healthcare, Commodity Trading, Real Estate Investment and Financial Services, of which Pharmaceuticals and Healthcare constitute the core business. CGE is ranked among the top five companies in China’s pharmaceutical industry and operates more than 60 pharmaceutical subsidiaries, with HMC being the largest.
About Sinclair Pharma
Sinclair Pharma is an international company operating in the fast growing global aesthetics market. Sinclair has built a strong portfolio of differentiated and complementary aesthetic technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high-quality, longer-lasting, natural-looking and minimally invasive treatments. Sinclair plans to enter several new geographic markets and launch line extensions over the next few years. The Group has an established sales and marketing presence in EU markets, Brazil, Mexico, ColombiaWATER, hong kong and South Korea and a network of international distributors. For more information, visit http://www.sinclairpharma.com.
About EMA Aesthetics
EMA Aesthetics, founded in 2019 and based in Ireland, is an international company specializing in the development and creation of advanced skin care technologies, focusing on combination therapy, which improve non-invasive aesthetic procedures, providing professional aesthetic products and services. EMA Aesthetics has offices in Ireland, Belgium, Singapore and the United Arab Emirates with a sales network that covers 30 countries and regions around the world. For more information, visit http://www.emaaesthetics.com.
Andy CraneSinclair Pharma, +44 (0) 20 7467 6920, [email protected]